Avalo Therapeutics, Inc. current report, 14 November 2019

Cerecor Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K was filed by Cerecor Inc. (Ticker: CERC) on November 14, 2019. The filing serves to announce the company's financial results for the quarter ended September 30, 2019. The registrant is an emerging growth company incorporated in Delaware.

Financial Metrics

The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the detailed financial results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference but not included in the text of this document.

Material Changes

No material changes or comparative financial data are disclosed within the body of this filing. The document acts solely as a notification that the quarterly results have been issued.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Key Facts for Investor Verification

  • Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached press release (Exhibit 99.1) referenced in this filing.
  • Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
  • Note that the financial data in this 8-K is not legally "filed" under Section 18 of the Exchange Act, limiting liability exposure for the forward-looking statements contained in the referenced press release.